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INTRODUCTION
Of newly diagnosed non-small cell lung cancer (NSCLC),
stage III cancer is approximately 30-40%. The prognosis of
patients with preoperative N2 disease treated with surgery
or radiation therapy alone is poor (1). In efforts to improve
local control and survival of patients with marginally resec-
table disease, various clinical trials particularly to determine
the optimal ways to combine thoracic radiation therapy (TRT),
chemotherapy, and surgery have been performed. Currently,
the most common method is the induction chemotherapy
with or without TRT and surgery, however, the results of
several randomized trials of preoperative chemotherapy and
surgery were conflicting (2-4). Non-randomized trials of pre-
operative concurrent radiochemotherapy (CRCT) produced
encouraging results (5-11), and these trials have a few draw-
backs as they may have included the patients with stage IIIB
based on inconsistent clinical nodal staging, accrued small
number of patients, and employed the various radiation and
chemotherapy dose schedules. 
We applied mediastinoscopic biopsy for potentially oper-
able NSCLC patients and recommended preoperative CRCT
and surgery for those with N2 disease. Here, we would report
the treatment outcomes and discussed the role of preopera-
tive CRCT and surgery.
MATERIALS AND METHODS 
We have adopted N-staging by mediastinoscopic biopsy
for potentially operable NSCLC patients. Fifty-three patients
with stage IIIA NSCLC with N2 disease confirmed by medi-
astinoscopic biopsy were treated with preoperative CRCT and
surgery from August 1997 till April 2001. The eligibility
for this treatment is that each patient should have 1) ECOG
performance score of 2 or lower, 2) no major medical illness
that might conflict with the aggressive treatment, 3) no sig-
nificant weight loss (less than 10% during recent 6 months),
4) no history of malignancy other than the current illness, and
5) adequate pulmonary, renal, hepatic, and hematologic re-
serves. The pretreatment work-ups for the diagnosis and stag-
ing included simple chest radiography, chest computerized
tomography (CT) scans, bronchoscopic evaluation with biop-
sy and/or washing cytology, complete blood counts, routine
urinalyses, chemistry profiles and whole-body bone scan. Ab-
dominal ultrasonography and brain CT or magnetic resonance
imaging were performed when clinically indicated.
The tri-modality treatment consists of preoperative CRCT
and surgery, and postoperative radiation therapy (PORT) was
optionally recommended for those with risk factors of loco-
regional recurrence based on the surgical and pathological
findings (Fig. 1). Preoperative CRCT consists of TRT (45 Gy/
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Preoperative Concurrent Radiochemotherapy and Surgery for Stage
IIIA Non-Small Cell Lung Cancer
This is to examine whether aggressive multimodality therapy improves the treatment
outcomes in stage IIIA non-small cell lung cancer (NSCLC). Fifty-three consecutive
NSCLC patients with N2 disease, confirmed by mediastinoscopic biopsy, received
preoperative thoracic radiation therapy (45 Gy/5 weeks) concurrent with two cycles
of oral etoposide and intravenous cisplatin and surgery. Postoperative radiation thera-
py (PORT, 18 Gy/2 weeks) was optionally recommended for those with the risk fac-
tors of loco-regional recurrence based on the surgical and pathological findings. Sur-
gical resection was performed in 38 patients (71.7%), and down-staging was achie-
ved in 19 patients (50%). The median survival period was 27 months in 38 patients
who underwent resection, and the rates at 3-yr of overall survival, loco-regional con-
trol, distant metastasis-free survival, and disease-free survival were 44.3%, 87.9%,
32.9%, and 29.3%. Significantly favorable factor regarding overall survival was achie-
ving p0/I stage by the multivariate analysis. PORT was successful in reducing loco-
regional recurrences in patients with the risk factors. Current preoperative concur-
rent radiochemotherapy and surgery by the authors resulted in comparable survival
with other reports, however, further refinement of multimodality approach may be
warranted for more effective reduction of distant metastasis.
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5 weeks) and two cycles of oral etoposide (100 mg/m
2/day,
days 1-14 and days 29-42) and intravenous cisplatin (100
mg/m
2, day 1 and day 29) that were concurrently delivered
during the TRT course. 10 MV radiography from a linear
accelerator were used in all patients’ TRT, and the TRT vol-
ume was individually determined to include the primary tu-
mor, the ipsilateral hilum and the mediastinum based on the
chest CT scans, but not the bilateral supraclavicular lymph
node areas. The radiation dose to the spinal cord was kept at
or below 45 Gy. Surgery was planned 4 to 6 weeks after CRCT
completion. PORT (18 Gy/2 weeks) was optionally recom-
mended for patients with risk factors of recurrence such as
incomplete resection, positive/close bronchial resection mar-
gin (no more than 5 mm), and high risk N1 or persistent N2
disease based on the surgical and pathological findings. We
defined high risk N1 disease as having any of the followings:
multiplicity; proximal location; and extracapsular extension.
The PORT volume mainly included the mediastinum, which
optionally was extended to cover the bronchial stump. 
Clinical response was evaluated by chest CT scans taken in
3 weeks of the completion of CRCT and just before surgery.
The pathologic response and the down-staging rates were
evaluated by thorough pathological examination. The regu-
lar follow-up examinations included chest CT scans and other
necessary laboratory tests. 
We analyzed the followings: 1) the overall compliance and
the resection rate, 2) the incidence and severity of the acute
side effects according to ECOG/RTOG toxicity criteria, 3)
the results of pathologic evaluation and the down-staging
rate, 4) the patterns of failure and survival results calculated
by the Kaplan-Meier method, and 5) the significance of the
possible prognostic factors by log-rank test. Survival was cal-
culated from the day 1 of CRCT.
RESULTS
Patients’ characteristics
The median age was 60 (37-75) yr, and the ratio of male
and female was 38:15. More patients were with adenocarci-
noma than squamous cell carcinoma (33 vs. 19), where ade-
nocarcinoma was far more common than squamous cell car-
cinoma among the female patients (14:1), while its incidence
was about the same as squamous cell carcinoma among the
male patients (19:18). The ECOG performance status was
good to excellent in most patients: 0-1 in 51 patients (96.2%);
and 2 in only 2 (3.8%). The degree of weight loss was 5% or
lower in the majority of patients (84.9%; 45/53), while it was
over 5% but not higher than 10% in 8 patients (15.1%). Cli-
nical T-stages based on chest CT scans and bronchoscopic
findings were cT1 in 7 patients, cT2 in 38, and cT3 in 8. The
chest CT criteria for the clinically metastatic mediastinal
lymph node(s) included that 1) the shortest dimension of
the affected lymph node should be equal to or greater than
1 cm (1.5 cm in case of subcarinal lymph node) and/or that
2) there should be the findings compatible with extracapsu-
lar extension or necrosis. Thirty patients (56.6%) were with
clinical N2 disease based on the chest CT findings. The char-
acteristics of patients are summarized in Table 1.
Treatment compliance
TRT was completed in 49 patients (92.5%), and four pa-
tients who developed either distant metastasis or severe side
effects during CRCT course could not complete TRT. Forty-
one patients (77.4%) could complete two cycles of chemother-
apy as planned, while twelve (22.6%) received only the first
cycle. Thoracotomy was attempted in 39 patients, and resec-
tion was performed in 38 patients, as one patient was with
unpredicted pleural seeding at the time of thoracotomy. The
resulting surgical resection rate was 71.7% (38/53). The rea-
sons for ‘no resection’ in 15 patients were as follows: six pa-
tients refused surgery; five developed loco-regional or distant
disease progression; and four had severe acute morbidity dis-
Preoprative concurrent radiochemotherapy
-Cisplatin+Etoposide #2q 4 weeks
-Thoracic radiation therapy 45 Gy/5 weeks
Postoperative radiation therapy
18 Gy/2 weeks
Observation
4-6 week
Risk factor (+) Risk factor (-)
Surgery
Fig. 1. Treatment scheme. Risk factors, by which the addition of
postoperative radiation therapy was considered, included incom-
plete resection, positive/close resection margins, pN2, and high-
risk pN1 diseases.
Number (%) Characteristics
Age (yr) <60 26 (49.1)
≥60 27 (50.9)
Sex Male 38 (71.7)
Female 15 (28.3)
Histology Squamous 19 (35.8)
Adenocarcinoma 33 (62.3)
Adenosquamous 1 ( 1.9)
Weight loss <5% 45 (84.9)
5-10% 8 (15.1)
ECOG performance score 0/1 51 (96.2)
2 2 ( 3.8)
T stages T1 7 (13.2)
T2 38 (71.7)
T3 8 (15.1)
Clinical N2 disease on chest CT  Absent 23 (43.4)
Present 30 (56.6)
Table 1. The characteristic of patientsPreoperative CRCT for Stage IIIA NSCLC 231
abling surgery. The surgery types were lobectomy in 27 pa-
tients (51.1%), bilobectomy in three (7.9%), and pneumonec-
tomy in eight (21.1%). In three patients complete mediasti-
nal lymph node dissection could not be performed: mediasti-
nal fibrosis in two patients; and invasion of the superior vena
cava and the pericardium by the lymph node in one patient.
After surgery, 24 patients had risk factors of recurrence, among
whom 17 patients received PORT, while seven refused PORT.
Acute morbidity and mortality
During CRCT, the most common grade III or IV acute
morbidity was neutropenia (58.5%; 31/53). Most non-hema-
tologic acute morbidities were grade 0-II: esophagitis in 51
patients (96.2%); nausea/vomiting in 52 patients (98.1%);
and acute lung toxicity in 51 patients (96.2%). Grade III
esophagitis, nausea/vomiting, and lung toxicity occurred in
2, 1, and 2 patients, respectively. Two treatment-related deaths
(3.8%) occurred: one died of sepsis after CRCT; and the other
died of respiratory failure after pneumonectomy and chest
wall resection. The details of acute morbidities are shown in
Table 2. 
Response to CRCT
Pathologic responses to preoperative CRCT were evaluat-
ed in 38 resected patients. Post-surgical T-stages were pT0
in three patients, pT1 in 18, pT2 in 13, pT3 in two, and pT4
(satellite nodules) in two. Post-surgical N-stages were pN0 in
17 patients, pN1 in two, and pN2 in 19. Post-surgical over-
all stages were p0 in one patient, pIA in nine, pIB in five,
pIIA in one, pIIB in three, pIIIA in 17, and pIIIB in two,
and down-staging was achieved in half of the patients (19/38).
Table 3 shows the changes of the stage after the completion
of preoperative CRCT. After resection, 24 patients had risk
factors of recurrence: pN2 was the most common in 19 pa-
tients; close or positive resection margins in seven patients;
incomplete resection in three patients; high-risk pN1 in one
patient; and chest wall invasion in one patient. 
Patterns of failure
The pattern of the first failure site was analyzed in 38 resect-
ed patients. Local recurrence (LR), regional recurrence (RR),
and distant metastasis (DM) were defined according to the
AJCC staging criteria. LR was observed in five patients (13.2
%), RR was in three (7.9%), and DM was in 24 (63.2%). The
patterns of LR were pleural seeding (PS) in three patients and
bronchial stump recurrence in two. All three patients with
RR also had simultaneous LR: two with mediastinal lymph
node recurrence had bronchial stump recurrence and PS, res-
pectively; and one with mediastinal and supraclavicular lymph
node recurrence had PS. Twenty-one patients developed DM
only, two did combined DM+LR, and one did combined
DM+LR+RR. 
The patterns of failure were somewhat different according
to the subgroups of patients based on the post-surgical risk
factors and the addition of PORT. Among 14 patients who
had no risk factors and did not receive PORT, only one devel-
oped combined PS+RR, and eight did DM, one of which was
within the TRT volume. Among 17 patients who had risk
factors and received PORT, only one developed combined
PS+DM, and 11 did DM only, all of which were also outside
the TRT volume. On the contrary, among seven patients who
had risk factors but did not receive PORT, one developed
combined LR (bronchial stump recurrence) +RR (mediasti-
nal lymph node), one did combined LR (bronchial stump re-
currence) +RR (mediastinal and supraclavicular lymph node)
+ DM, and one did combined PS+DM, two of which were
within the TRT volume (Fig. 2).
Survivals
The median follow-up period for the survivors was 48 mon-
ths (range: 20-74 months). For all 53 patients, the median
survival duration was 22 months, and the 3- and 5-yr overall
survival (OS) rates were 34.9% and 25.7%. In 38 patients who
underwent surgical resection, the median survival duration
was 27 months, and the 3- and 5-yr OS rates were 44.3% and
32.7%. In 15 patients who did not undergo surgical resection,
the median survival duration was 12 months, and the 3-yr
OS rate was 10%. In the patients who underwent surgical
resection, the median disease-free interval was 16 months, the
3- and 5-yr disease-free survival (DFS) rates were 29.3% and
T-stage N-stage AJCC stage
Down-staged 18 19* 19
�(50.0%)
No change 16 19 17 (44.7%)
Up-staged 4 0 2
�( 5.3%)
Table 3. The disease stage after preoperative concurrent radio-
chemotherapy and surgery (n=38)
*pN0 in 17 and pN1 in 2 patients. 
� pathologic CR in 1, pIA in 9, pIB in 5,
pIIA in 1, and pIIB in 3 patients. 
� pIIIB in 2 patients because of unfore-
seen pleural seeding.
01 2 3 4 5 Grade
Hematologic
WBC 4 4 14 23 7 1
Platelet 41 3 3 2 4 0
Hemoglobin 13 17 17 6 0 0
Non-hematologic
Esophagitis 11 21 19 2 0 0
Nausea/vomiting 23 14 15 1 0 0
Acute lung toxicity* 32 15 4 2 0 0
Table 2. Acute morbidity and mortality during concurrent radio-
chemotherapy
*One patient died of respiratory failure after pneumonectomy and chest
wall resection.232 M.K. Kang, Y.C. Ahn, D.H. Lim, et al.
25.6%, the 3- and 5-yr loco-regional control (LRC) rates and
distant metastasis-free survival (DMFS) rates were 87.9% and
81.6%, and 32.9% and 28.8%, respectively (Fig. 3, 4).
Prognostic factors
The prognostic implication of the possible prognostic fac-
tors including age, sex, histology, PORT, preoperative T-stage,
postoperative T-stage, postoperative N-state, and postopera-
tive overall stage were analyzed in 38 patients who underwent
surgical resection. By the univariate analysis, surgical resec-
tion, achieving pN0, and achieving p0/I stage were signifi-
cant favorable factors with respect to OS. With respect to DFS,
achieving pN0 and p0/I stage were significant favorable factors.
With respect to DMFS, low preoperative T-stage, achieving
lower pT-stage (pT0/1 vs. pT2/3), achieving pN0, and achiev-
ing p0/I stage were significant favorable prognostic factors.
For LRC, PORT was a significant favorable factor. By the
multivariate analysis, only achieving p0/I stage was significant
with respect to OS (Fig. 5, Table 4).
DISCUSSION
In newly diagnosed NSCLC patients, those with locally
advanced stage III disease comprise approximately 30% to
40%. The stage IIIA NSCLC is a heterogenous group that
includes unforeseen N2 disease that is unknown until thora-
cotomy, mediastinoscopic N2 disease, and clinically overt N2
disease based on chest CT scan (1). In unforeseen N2 disease,
the complete resection rate ranged from 53% to 87%, and
the long term survival rates ranged from 20% to 30% (12).
In patients with N2 disease detected by radiologic or medi-
astinoscopic findings, the long-term survival rate following
17 with risk factor
PORT (+)
Fig. 2. The patterns of failure in relation to post-surgical risk factors
and postoperative radiation therapy (PORT). DM, distant metasta-
sis; LR, local recurrence; NED, no evidence of disease; PS, pleu-
ral seeding; RR, regional recurrence. Asterisk denotes failure within
the thoracic radiation therapy volume.
7 with risk factor
PORT(-)
14 with no risk
factor
Incomplete
resection in 3
Complete
resection in 35
38 patients
underwent resection
4 NED 
1 postop. death 
1 PS+RR* 
8 DM
5 NED 
1 PS+DM 
11 DM
2 NED 
1 LR*+RR* 
1 LR*+RR*+DM 
1 PS+DM 
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Fig. 3. Overall survival rates.
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Fig. 4. Disease-free survival rates of 38 patients who underwent
resection. DFS, disease-free survival rate; LRRFS, loco-regional
recurrence-free survival rate; DMFS, distant metastasis-free sur-
vival rate.
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Fig. 5. The influence of postoperative stage on distant metasta-
sis-free survival.
65.5%
0%
65.5%
30.4%resection was usually lower than 10%, and these patients thus
were thought to be unsuitable for upfront curative surgery
(13, 14). To improve the local control and survival of patients
with such marginally resectable or unresectable N2 disease,
various clinical trials have been performed to find the optimal
ways to combine TRT, chemotherapy, and surgery. 
The potential advantages of the preoperative treatment
strategy are the increased resection rate, decreased micrometa-
stasis, and decreased surgical seeding, while the potential di-
sadvantages are the possible delay in primary surgery and the
increased surgical morbidity and mortality (15). Preoperative
TRT and surgery, based on a few randomized trials, failed to
improve survival rate when compared with surgery alone (16,
17). PORT for the patients with pN2 disease was the usual-
ly recommended practice, which, however, only contributed
to the improvement in the loco-regional control, but not to
the survival benefit (18). Most recent clinical trials, hence,
applied preoperative chemotherapy and/or TRT and surgery
for marginally resectable stage IIIA NSCLC. Randomized
trials employing preoperative chemotherapy, however, showed
controversial effects on the overall survival (2-4, 19). There
are a few reports that survival rates were improved by preop-
erative chemotherapy (2, 3), however, these results were not
conclusive as they are based on rather small number of patients,
included patients with stage IIIB, and used inconsistent sur-
gical nodal staging. Recent phase III report comparing pre-
operative chemotherapy and surgery versus surgery alone on
histologically confirmed N2 positive stage IIIA NSCLC, failed
to document the survival benefit by adding preoperative che-
motherapy (median survival durations were 17 months and
16 months, respectively. p=0.527) (4).
There are less reports on preoperative CRCT and surgery
than preoperative chemotherapy and surgery (5-10). More-
over, most of them were nonrandomized trials with a small
number of patients, used inconsistent surgical nodal staging,
included stage IIIB patients, and used variable dose schedules
of TRT. Their results are generally encouraging, however.
SWOG 8805 used conventional TRT (45 Gy, 1.8 Gy/frac-
tion), concurrently with two cycles of cisplatin and etoposide
for the patients with N2 or N3 disease proven by biopsy, and
added CRCT boost if positive margins or positive nodes were
detected on surgical specimen (5). The median survival dura-
tion was 13 months and the 3-yr overall survival rate was 27
%. Choi et al. (6) used hyperfractionated TRT (42 Gy, 1.5
Gy/fraction, twice a day), concurrently with two cycles of
chemotherapy (cisplatin, vinblastine, and fluorouracil) for the
patients with N2 disease confirmed by mediastinoscopy, and
administered postoperative TRT (12-18 Gy, 1.5 Gy/fraction,
twice a day) concurrently with one cycle of chemotherapy.
The median survival duration was 25 months and the 3-yr
overall survival rate was 37%. We used conventional TRT
(total 45 Gy, 1.8 Gy/fraction), concurrently with two cycles
of cisplatin and etoposide for the patients with N2 disease
confirmed by mediastinoscopy, and optional PORT if persis-
tent N2 disease, positive/close resection margin, or high-risk
N1 disease were found. In 38 resected patients, the median
survival duration was 27 months and the 3-yr overall survival
rate was 44%. A common finding of these three studies is
that the survival benefit was observed in those who achieved
down-staging following preoperative CRCT. Our study sho-
wed that the survival rate of the patients who achieved pN0
after preoperative CRCT was significantly increased compar-
ed with those who did not achieve pN0. Likewise, in SWOG
8805, the median survival durations and the 3-yr survival
rates in patients with negative and positive lymph nodes on
surgery were 30 months and 9 months, and 41% and 11%,
respectively (5). Similar results were reported by Choi et al.
(6): the 5-yr survival rates in patients with the postsurgical
stage 0/I, II, and III were 79%, 42%, and 18%, respectively.
Bueno et al. (20) also reported that pN0 after preoperative
treatment was a favorable prognostic factor, where the 3-yr
survival rates for the postsurgical state 0/I or II/III patients
were 65% and 30%, respectively.
Recently, the long-term outcome of phase III randomized
trial (INT 0139) comparing preoperative CRCT (45 Gy)
and surgery with definitive CRCT (61 Gy) was reported (10).
Although there was no significant difference in overall survival
between two arms (median survival: 23.6 vs. 22.2 months,
p=0.24; 5-yr survival: 27.2% vs. 20.3%, p=0.10), progression-
free survival was significantly improved by adding surgical
resection (median progression-free survival: 12.8 vs. 10.5 mon-
ths, p=0.017; 5-yr progression-free survival: 22.4% vs. 11.1%,
p=0.008). The treatment-related mortality rate, however, was
higher by surgical resection (7.9% vs. 2.1%, p=0.021), espe-
cially when pneumonectomy was necessary, and achieving
pN0 stage significantly improved long-term survival com-
pared with pN1-3 and no surgery (41% vs. 24% vs. 8%, p<
0.0001). 
Roberts et al. (21) reported that preoperative treatment
might have increased the perioperative morbidity and mor-
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Univariate Multivariate
p-value Favorable 
prognostic factors
End point
Among all patients (n=53)
Overall survival Surgical resection 0.0005 -
Among patients who underwent resection (n=38)
Overall survival Achieving pN0  0.0194 0.3447
Achieving p0/I stage  0.0035 0.0232
Disease free survival Achieving pN0 0.0412 0.7148
Achieving p0/I stage 0.0197 0.1872
Distant metastasis  Lower cT stage 0.0234 0.2382
free survival Achieving pT0/1 0.0311 0.1203
Achieving pN0 0.0427 0.8292
Achieving p0/I stage 0.0191 0.1213
Among patients with pN2 after resection (n=19)
Loco-regional control Postoperative thoracic 0.0039 -
radiation therapy
Table 4. Prognostic factorstality, while, however, others reported no increased risk (22,
23). Choi et al. (6) and Weitberg et al. (7) reported approxi-
mately 5% perioperative mortality rates. In our study, only
one patient died after pneumonectomy. Preoperative CRCT
and surgery performed under the strong team work of the
expert specialists is an important factor to improve the sur-
vival without increasing perioperative morbidity and mor-
tality (24).
Although preoperative CRCT has been reported to effec-
tively lower local recurrence in patients with locally advanced
NSCLC, the optimal dose schedule of radiation therapy is yet
unclear. Vora et al. (8) applied high dose TRT (total 59.4 Gy)
concurrently with chemotherapy followed by surgery in 33
patients with stage IIIA or IIIB NSCLC, and reported that
no local failure was observed among 9 patients who achieved
complete pathologic response following preoperative CRCT
(27%). Weitberg et al. (7), who applied 55.8 Gy preoperative
TRT concurrently with chemotherapy in 27 stage IIIA pa-
tients, reported that tumors were not detected in 44% of the
resection specimens (12/27), among who two patients devel-
oped local relapse. These suggest that preoperative CRCT
with high dose TRT be an effective way to improve local con-
trol. SWOG 8805 (5) applied boost CRCT (14.4 Gy) to pa-
tients with unresectable disease, positive margin, incomplete
resection, or positive mediastinal nodes, and reported that the
grade 4 toxicities occurred in 11% of the patients and three
mortality cases were related to boost CRCT. Choi et al. (6)
applied 12 Gy boost CRCT to the patients with pathologic
complete or near complete remission, or alternately, 18 Gy
boost CRCT to the patients with residual disease at the resec-
tion margins or resected specimen, however, did not analyze
the impact of boost CRCT. We applied less aggressive TRT
dose (45 Gy) and decided to add boost irradiation optionally
based on the surgical and pathologic findings. There were
two recurrences within the TRT volume among 7 patients
who were with risk factors but did not receive PORT, how-
ever, there was only one recurrence within the TRT volume
among 14 patients who had no risk factors and did not receive
PORT, and no loco-regional recurrence within the TRT vol-
ume among 17 patients who had risk factors and received
PORT. Hence, our treatment protocol of adding PORT optio-
nally based on the surgical and pathologic findings is consid-
ered quite reasonable in the respect of selecting the patients
who would have more benefit from PORT. In general, PORT,
however, did not influence distant metastasis, disease-free
survival, and overall survival. Study with more patients and
longer follow-up would be necessary to investigate the exact
role of PORT.
In many studies with preoperative CRCT including ours,
distant metastasis occurred in 40% to 60% of patients, where-
as loco-regional failure occurred in approximately 10% (5, 6,
8, 11). It has been shown that the response to the preoperative
chemotherapy or CRCT has the impact on survival rate (5,
6, 20). Therefore, further study is needed to develop more
effective chemotherapy regimen that can prevent distant meta-
stasis and improve the response to the preoperative treatment.
By applying preoperative CRCT and surgery for N2 posi-
tive stage IIIA NSCLC patients, authors could achieve imp-
roved survival results comparable with other reports. The
postoperative disease stage is a significant prognostic factor
of overall survival, and further refinement of multimodality
combined treatment approach for more effective reduction
of distant metastasis may be warranted.
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